<!DOCTYPE html
  SYSTEM "about:legacy-compat">
<html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8"><meta name="copyright" content="(C) Copyright 2023"><meta name="DC.rights.owner" content="(C) Copyright 2023"><meta name="DC.Type" content="concept"><meta name="DC.Relation" scheme="URI" content="27.204.html"><meta name="DC.Format" content="XHTML"><meta name="DC.Identifier" content="FAR_27_204_1"><link rel="stylesheet" type="text/css" href="commonltr.css"><link rel="stylesheet" type="text/css" href="gsa-base.css"><title>27.204-1 Use of patented technology under the United States-Mexico-Canada Agreement.</title></head><body><main role="main"><article role="article" aria-labelledby="ariaid-title1">
   <article class="nested0" aria-labelledby="ariaid-title1" id="FAR_27_204_1">
      <h1 class="title topictitle1" id="ariaid-title1">
         <span class="ph autonumber">27.204-1</span> 
         Use of patented technology under the United States-Mexico-Canada Agreement.
      </h1>
      <div class="body conbody">
         <p class="p" id="FAR_27_204_1__d1755e11">
            When questions arise with regard to use of patented technology under the United States-Mexico-Canada Agreement, the contracting officer should consult with legal counsel. Note that Article 20.6(a) of the Agreement discusses public health and pharmaceuticals.
         </p>
      </div>
   <nav role="navigation" class="related-links"><div class="familylinks"><div class="parentlink"><strong>Parent topic:</strong> <a class="link FAR_27_204 FAR_Subpart_27_2 FAR_Part_27 FAR_5 FAR_Subchapter_ENoPropFAR_27_204.htmlsubtopic" href="27.204.html">27.204 Patented technology under trade agreements.</a></div></div></nav></article>
</article></main></body></html>